Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:22:40 29/05/2024 BST			5-day change	1st Jan Change
0.757 ^USD	-8.39%		-8.30%	-36.92%

04-11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
03-13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Eloxx Pharmaceuticals, Inc. Appoints Neil Belloff as Executive Vice President, General Counsel and Corporate Secretary

June 18, 2018 at 12:30 pm

Eloxx Pharmaceuticals, Inc. announced that it has appointed Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary of the company. Mr. Belloff joins the company from Celgene Corporation where he served as Senior Corporate Counsel since 2011.

Latest news about Eloxx Pharmaceuticals, Inc.

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	03-13	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	03-13	MT
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement	01-09	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	12-28	CI
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	12-15	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating	11-02	MT
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index	18/10/23	CI
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index	13/10/23	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	15/09/23	CI
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating	14/09/23	MT
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013	07/09/23	CI
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	14/08/23	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Top Premarket Gainers	12/07/23	MT
Top Midday Gainers	11/07/23	MT
Oppenheimer Adjusts Eloxx Pharmaceuticals' Price Target to $55 From $50, Keeps Outperform Rating	11/07/23	MT
Transcript : Eloxx Pharmaceuticals, Inc. - Shareholder/Analyst Call	27/06/23
Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients	14/06/23	CI
Top Premarket Decliners	16/05/23	MT
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013	02/05/23	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI

Chart Eloxx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.757 USD

Average target price

30 USD

Spread / Average Target

+3,863.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELOXX PHARMACEUTICALS, INC.	-36.92%	2.5M
VERTEX PHARMACEUTICALS INCORPORATED	+7.28%	114B
REGENERON PHARMACEUTICALS, INC.	+8.63%	104B
ARGENX SE	+0.23%	22.57B
BIONTECH SE	-11.38%	22.5B
GENMAB A/S	-10.53%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-14.90%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+2.75%	13.55B
SAREPTA THERAPEUTICS, INC.	+27.39%	10.99B

Bio Therapeutic Drugs